Boehringer's Praxbind gets European approval for specific reversal of Pradaxa

Boehringer Ingelheim has received approval from the European Commission for Praxbind (idarucizumab), a treatment designed to quickly reverse the anticoagulant effects of Pradaxa (dabigatran etexilate) in cases of emergency surgery or in situations of…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news